Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription 13.10.2025 5 Am J Gastroenterol 1 Am J Pathol 3 Biochem Biophys Res Commun 4 BMC Cancer 7 BMC Gastroenterol 1 Br J Surg 1 Cancer 6 Clin Res Hepatol Gastroenterol 4 Dig Dis Sci 6 Endoscopy 1 Eur J Pediatr 8 Eur Radiol 5 Gut 6 Hepatology 2 Int J Cancer 1 J Gastroenterol 4 J Gastroenterol Hepatol 12 J Hepatol 2 Oncogene 4 PLoS One 1 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. PATEL AA, O'Leary JG, Bajaj JS, Prause N, et al
   Increasing Goals of Care Discussions Among Veterans with Cirrhosis: A Veterans Health Administration Quality Improvement Initiative.
   Am J Gastroenterol. 2025 Sep 29. doi: 10.14309/ajg.0000000000003781.
   PubMed         Abstract available
   
   
2. BROWN CL, Bajaj JS
   Considerations in the Diagnoses and Management of Hepatic Disease in Older Adults.
   Am J Gastroenterol. 2025;120.
   PubMed        
   
   
3. LUTZ MK, Caldera F
   Vaccination Outcomes and Recommendations Among Older Adults in a Gastroenterology and Hepatology Practice.
   Am J Gastroenterol. 2025;120.
   PubMed        
   
   
4. BOIKE JR, Gallegos-Orozco JF, Duarte-Rojo A
   Rallentando un Poco : Carvedilol and Its Role in Cirrhosis Progression.
   Am J Gastroenterol. 2025 Oct 3. doi: 10.14309/ajg.0000000000003765.
   PubMed        
   
   
5. ZHANG X, Ning C, Yang X
   The Illusion of Response: Diffuse Hepatic Metastasis Masked by Shrinking Lesions in Neuroendocrine Carcinoma of the Cervix.
   Am J Gastroenterol. 2025 Oct 10. doi: 10.14309/ajg.0000000000003788.
   PubMed        
   
   

   
   Am J Pathol

6. JAIN S, Mukherjee R, Williams G, Liu JJ, et al
   Hepatocyte-specific MET deletion exacerbates acetaminophen-induced hepatotoxicity in mice.
   Am J Pathol. 2025 Sep 30:S0002-9440(25)00367.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

7. DU A, Ma X, Huang T, Pan H, et al
   Time-series transcriptome profiling of liver regeneration in ALLPS models of mice identifies the Cyp8b1 as a potential target for hepatocyte proliferation.
   Biochem Biophys Res Commun. 2025;785:152690.
   PubMed         Abstract available
   
   
8. WEI WJ, Lin C, Luo SH, Huang JJ, et al
   FAM3B activates hepatic stellate cells to accelerate hepatic fibrosis by promoting glucose metabolism.
   Biochem Biophys Res Commun. 2025;786:152703.
   PubMed         Abstract available
   
   
9. CHARMANNA SO, Karunakara SH, Srinivasa S, Panchakshari PM, et al
   Dietary short-chain fatty acid Sodium Butyrate orchestrates pro-apoptotic and anti-angiogenic pathways in HCC cells by targeting the novel SND1/hTERT axis.
   Biochem Biophys Res Commun. 2025;784:152651.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. LEI L, Shi W, Yang X, Lin J, et al
    Syntaxin-7 promotes EMT and tumor progression via NF-kappaB signaling and is associated with macrophage infiltration: pan-cancer analysis and experimental validation in hepatocellular carcinoma.
    BMC Cancer. 2025;25:1430.
    PubMed         Abstract available
    
    
11. WU Y, Li L, Shi C, Bu X, et al
    Complications and management of bronchobiliary fistula following microwave ablation for hepatic malignancy: a retrospective analysis.
    BMC Cancer. 2025;25:1537.
    PubMed         Abstract available
    
    
12. LIU SY, Zhu L, Lu WF, Xie GL, et al
    Preoperative HBsAg seroclearance affects long-term outcomes for hepatitis B virus-related hepatocellular carcinoma after liver resection: a multicenter analysis.
    BMC Cancer. 2025;25:1467.
    PubMed         Abstract available
    
    
13. ZHU L, Li N, Liang S, Jiang B, et al
    High frame rate contrast-enhanced ultrasound in hepatocellular carcinoma: biological characteristics and patient outcomes.
    BMC Cancer. 2025;25:1488.
    PubMed         Abstract available
    
    

    
    BMC Gastroenterol

14. ZAN W, Yang J, Zhou Y
    Retrospective study: analysis of risk factors and construction of prediction model for pancreatic steatosis.
    BMC Gastroenterol. 2025;25:708.
    PubMed         Abstract available
    
    
15. YUE B, Yang D, Lu Z, Zhao S, et al
    Partial Splenic embolization combined with endoscopic variceal ligation in variceal rebleeding prevention among liver cirrhosis patients complicated with hypersplenism, thrombocytopenia, and esophagogastric variceal hemorrhage: a prospective observati
    BMC Gastroenterol. 2025;25:696.
    PubMed         Abstract available
    
    
16. JIA S, Ye X, Wu T, Wang Z, et al
    Global prevalence of metabolic dysfunction-associated fatty liver disease in children and adolescents with overweight and obesity: a systematic review and meta-analysis.
    BMC Gastroenterol. 2025;25:691.
    PubMed         Abstract available
    
    
17. PENG L, Ai M
    Association of serum osmolality with metabolic dysfunction-associated steatotic liver disease in adults.
    BMC Gastroenterol. 2025;25:693.
    PubMed         Abstract available
    
    
18. OUEDRAOGO K, Toure AO, Bocoum FY, Diallo D, et al
    Evaluation of the direct cost of chronic viral hepatitis B in patients monitored at the hepato-gastroenterology department of the Yalgado OUEDRAOGO University Hospital.
    BMC Gastroenterol. 2025;25:717.
    PubMed         Abstract available
    
    
19. RANJBAR BK, Taghizadeh M, Ebrahimpour-Koujan S, Yekaninejad MS, et al
    The effect of a plant- and dairy-based protein diet on serum levels of inflammatory and oxidative stress biomarkers in patients with liver cirrhosis: a randomized controlled trial.
    BMC Gastroenterol. 2025;25:695.
    PubMed         Abstract available
    
    
20. CHEN C, Ren Y, Li Y, Jiang S, et al
    Long-term efficacy of transarterial chemoembolization in the treatment of recurrent hepatocellular carcinoma.
    BMC Gastroenterol. 2025;25:657.
    PubMed         Abstract available
    
    

    
    Br J Surg

21. HALLET J, Acher AW, Jivraj N, McIsaac DI, et al
    Association between anaesthetist hepatopancreatobiliary volume and outcomes.
    Br J Surg. 2025;112:znaf192.
    PubMed        
    
    

    
    Cancer

22. FOLKERTS AD, Janczewski LM, Merkow RP
    Liver-directed therapies for colorectal liver metastases.
    Cancer. 2025;131:e70097.
    PubMed         Abstract available
    
    

    
    Clin Res Hepatol Gastroenterol

23. ELNAGGAR M, Hassan I, Eltaly H, Obeid A, et al
    Evolving end-of-life care patterns for hepatocellular carcinoma in the United States: A 25-year national analysis of disparities in home and hospice utilization.
    Clin Res Hepatol Gastroenterol. 2025;49:102686.
    PubMed         Abstract available
    
    
24. HEXNER-ERLICHMAN Z, Assy N, Habashi N, Yousif A, et al
    Multiorgan fibrosis in Gaucher disease type I: an unmet goal of enzyme replacement therapy.
    Clin Res Hepatol Gastroenterol. 2025;49:102677.
    PubMed         Abstract available
    
    
25. COSAR OS, Ozturk H, Kayhan G, Can A, et al
    GGT-normal cholestasis associated with LSR deficiency: A potential new subtype of PFIC.
    Clin Res Hepatol Gastroenterol. 2025;49:102674.
    PubMed         Abstract available
    
    
26. SOPHASATH M, Tremblay M, Hogue C, Brisset A, et al
    Evaluation of a nutritional education guide designed for patients living with cirrhosis: A randomized controlled mixed-methods study.
    Clin Res Hepatol Gastroenterol. 2025;49:102672.
    PubMed         Abstract available
    
    
27. JABER H, Chehayeb S, Nasr J, Souky NA, et al
    Proton Pump Inhibitor Use and Risk of Hepatic Encephalopathy in Cirrhotic Patients: A Systematic Review and Meta-Analysis.
    Clin Res Hepatol Gastroenterol. 2025 Aug 12:102667.
    PubMed         Abstract available
    
    
28. AZIMI A, Jolfayi AG, Rezayifar V, Ateen F, et al
    The association between metabolic-associated fatty liver diseases and risk of colorectal polyps, neoplasia, and cancer: A systematic review and meta-analysis of over 56 million individuals.
    Clin Res Hepatol Gastroenterol. 2025;49:102652.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

29. RODRIGUES SG
    NIT Picking-How the Careful Selection of Non-invasive Tools Has Improved the Diagnosis of Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease.
    Dig Dis Sci. 2025 Sep 30. doi: 10.1007/s10620-025-09440.
    PubMed        
    
    
30. TIE G, Shao S, Shuang J, He Q, et al
    A Rare Anomaly of Cystic Duct Drainage into a Variant Right Hepatic Duct: Cholangioscopy Diagnosis and Management.
    Dig Dis Sci. 2025 Sep 28. doi: 10.1007/s10620-025-09434.
    PubMed        
    
    
31. CHEN Y, Feng H, Bao Y, Yan M, et al
    Cost-Effectiveness of Risk-Score-Based Surveillance Strategies for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.
    Dig Dis Sci. 2025 Sep 27. doi: 10.1007/s10620-025-09419.
    PubMed         Abstract available
    
    
32. ACHARYA R, Soundararajan R, Gupta P, Gupta R, et al
    EUS-Guided Diagnosis of Hepatic Tuberculosis Presenting as Postoperative Fistula.
    Dig Dis Sci. 2025 Sep 23. doi: 10.1007/s10620-025-09421.
    PubMed        
    
    

    
    Endoscopy

33. TAKANO Y, Tamai N, Yamawaki M, Noda J, et al
    Troubleshooting guidewire perforation of the bile duct during endoscopic ultrasound-guided hepaticogastrostomy using the liver impaction technique.
    Endoscopy. 2025;57.
    PubMed        
    
    
34. OGURA T, Matsuno J, Kanadani T, Nakamura J, et al
    Pitfall of endoscopic ultrasound-guided hepaticoduodenostomy: Impact of hepatic parenchymal volume during device insertion.
    Endoscopy. 2025;57.
    PubMed        
    
    
35. DING S, Shen T, Zhu H, Hu Y, et al
    Esophageal metastasis from hepatocellular carcinoma after orthotopic liver transplantation.
    Endoscopy. 2025;57.
    PubMed        
    
    
36. HIROSHIMA Y, Sagami R, Azuma Y, Tsuji H, et al
    Calculus-targeted puncture technique to overcome access difficulty during endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2025;57.
    PubMed        
    
    
37. SATO R, Matsumoto K, Matsumi A, Miyamoto K, et al
    Salvaging hilar access using an uneven double-lumen cannula in endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2025;57.
    PubMed        
    
    
38. MIWA H, Tsunoda S, Endo K, Oishi R, et al
    A novel slim cholangioscope facilitates antegrade laser lithotripsy for an intrahepatic biliary stone with acute ductal angulation.
    Endoscopy. 2025;57.
    PubMed        
    
    

    
    Eur J Pediatr

39. LI X, Xue J, Tang X, Zhang J, et al
    Prognostic factors and treatment outcomes of hepatoblastoma in children: a SEER database analysis.
    Eur J Pediatr. 2025;184:666.
    PubMed         Abstract available
    
    

    
    Eur Radiol

40. LEE DH, Lee JM
    Toward personalized hepatocellular carcinoma treatment using liver MRI: predicting intratumoral tertiary lymphoid structure maturity.
    Eur Radiol. 2025 Oct 7. doi: 10.1007/s00330-025-11992.
    PubMed        
    
    
41. PARK JH, Goh MJ, Sinn DH, Shin J, et al
    Predicting early progression to atezolizumab-bevacizumab in hepatocellular carcinoma: a clinical and imaging-based scoring system.
    Eur Radiol. 2025 Oct 4. doi: 10.1007/s00330-025-12040.
    PubMed         Abstract available
    
    
42. XU M, Yin S, Zhao Q, Tian G, et al
    Recurrence patterns and survival outcomes after irreversible electroporation for hepatocellular carcinoma: a 6-year multicenter experience.
    Eur Radiol. 2025 Oct 3. doi: 10.1007/s00330-025-12044.
    PubMed         Abstract available
    
    
43. CAI W, Zhu Y, Li D, Wang B, et al
    Intratumoral heterogeneity of CT enhancement for component prediction and prognostic significance in combined hepatocellular carcinoma?cholangiocarcinoma.
    Eur Radiol. 2025 Oct 2. doi: 10.1007/s00330-025-12034.
    PubMed         Abstract available
    
    
44. GANDON Y, Chau THT, Borde P, Bannier E, et al
    Comparison of hepatic iron quantification by MRI between 1.5 and 3 T, using different methods and conversion formulas.
    Eur Radiol. 2025 Sep 27. doi: 10.1007/s00330-025-12027.
    PubMed         Abstract available
    
    
45. CHEN H, Zhu J, Zhou J, Yin Z, et al
    Correction: MR elastography-based prediction of development of hepatocellular carcinoma in patients with chronic hepatitis B with sustained virological response.
    Eur Radiol. 2025 Sep 22. doi: 10.1007/s00330-025-12012.
    PubMed        
    
    
46. YAMAMOTO A, Sato S, Ueda D, Walston SL, et al
    Deep-learning-based prediction of significant portal hypertension with single cross-sectional non-enhanced CT.
    Eur Radiol. 2025 Sep 22. doi: 10.1007/s00330-025-12010.
    PubMed         Abstract available
    
    
47. WANG Z, Liang Q, Luo J, Liao Y, et al
    Detection of macrotrabecular-massive hepatocellular carcinoma based on viscoelastic characteristics obtained by multifrequency magnetic-resonance elastography.
    Eur Radiol. 2025 Oct 9. doi: 10.1007/s00330-025-12024.
    PubMed         Abstract available
    
    

    
    Gut

48. BUELONI B, G Fernandez-Barrena M, Fiore E, Avila MA, et al
    Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications.
    Gut. 2025 Sep 23:gutjnl-2025-336317. doi: 10.1136/gutjnl-2025-336317.
    PubMed         Abstract available
    
    
49. SHEN Y, Jin X, Song W, Fang T, et al
    Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies.
    Gut. 2025 Sep 29:gutjnl-2025-335904. doi: 10.1136/gutjnl-2025-335904.
    PubMed         Abstract available
    
    
50. XU W, Zhao Y, Weng J, Yu M, et al
    Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma.
    Gut. 2025 Oct 7:gutjnl-2025-336374. doi: 10.1136/gutjnl-2025-336374.
    PubMed         Abstract available
    
    
51. VANDERSCHUEREN E, Praktiknjo M, Wiest R, Cardenas A, et al
    Recent advances in clinical practice endohepatology: the endoscopic liver rush.
    Gut. 2025;74:1916-1930.
    PubMed         Abstract available
    
    
52. LIU Y, Wang T, Zhang F, Liu X, et al
    Crosstalk between liver sinusoidal endothelial cells and hepatocytes via IL-1alpha-IL1R1 axis exacerbates ischaemia/reperfusion injury in aged livers.
    Gut. 2025 Oct 8:gutjnl-2025-335964. doi: 10.1136/gutjnl-2025-335964.
    PubMed         Abstract available
    
    

    
    Hepatology

53. MA H, Zhang VX, Tsui YM, Lee JM, et al
    Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma.
    Hepatology. 2025 Oct 9. doi: 10.1097/HEP.0000000000001561.
    PubMed         Abstract available
    
    
54. HUANG X, Lisman T
    Cirrhotic portal vein thrombosis as a vascular rather than a thrombotic disorder.
    Hepatology. 2025 Oct 8. doi: 10.1097/HEP.0000000000001565.
    PubMed        
    
    
55. FOERSTER F, Wiesmann L, Bark P, Galle PR, et al
    Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma.
    Hepatology. 2025 Oct 2. doi: 10.1097/HEP.0000000000001554.
    PubMed         Abstract available
    
    
56. WANG X, Luo J, Han L, Xu T, et al
    FXR splicing by SF3B3 promotes MYC-driven hepatocarcinogenesis.
    Hepatology. 2025 Sep 23. doi: 10.1097/HEP.0000000000001523.
    PubMed         Abstract available
    
    
57. PREMKUMAR M, Kajal K, Roy A, Izzy M, et al
    'Point-of-Care Ultrasound (POCUS) guided volume management and the effect of cirrhotic cardiomyopathy on acute kidney injury outcomes in cirrhosis'.
    Hepatology. 2025 Sep 23. doi: 10.1097/HEP.0000000000001524.
    PubMed         Abstract available
    
    
58. ABAD-JORDA L, Andres-Rozas M, Martinez-Alcocer A, Aspas J, et al
    Hepatocyte-derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p - pyroptosis axis.
    Hepatology. 2025 Oct 10. doi: 10.1097/HEP.0000000000001567.
    PubMed         Abstract available
    
    

    
    Int J Cancer

59. LUO S, Qiao S, Liu L, Jia Y, et al
    Comprehensive molecular characterization of Rho GTPases and their regulators across human cancers.
    Int J Cancer. 2025;157:2309-2324.
    PubMed         Abstract available
    
    
60. HAN Y, Shaw VR, Byun J, Thrift AP, et al
    Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits.
    Int J Cancer. 2025 Sep 27. doi: 10.1002/ijc.70136.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

61. MIYAKE T, Yoshida O, Furukawa S, Sato Y, et al
    GPAM upregulation enhances hepatic fat deposition and reduces visceral adipose tissue in response to trans-fatty acids.
    J Gastroenterol. 2025 Oct 4. doi: 10.1007/s00535-025-02297.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

62. KIM MN, Park GU, You SC, Lee JS, et al
    Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis.
    J Gastroenterol Hepatol. 2025 Oct 1. doi: 10.1111/jgh.70078.
    PubMed         Abstract available
    
    
63. KO KA, Oh H, Kim MS, Hong HP, et al
    Role of ALBI Grade as a Predictive Factor for Long-Term Mortality in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    J Gastroenterol Hepatol. 2025 Oct 3. doi: 10.1111/jgh.70098.
    PubMed         Abstract available
    
    
64. VIJAYALEKSHMI B, Chaudhary A, Prabhu SB, Sharma A, et al
    Plasma-Driven Monocyte Dysfunction Drives Disease Progression in Alcohol-Related Acute-on-Chronic Liver Failure.
    J Gastroenterol Hepatol. 2025;40:2591-2600.
    PubMed         Abstract available
    
    
65. ZENG X, Li Z, Chen Y, Yao H, et al
    Impairing Islets in Newborn Mice Promotes Liver Fibrosis and Carcinoma Development in a Rapid NASH Model.
    J Gastroenterol Hepatol. 2025;40:2601-2612.
    PubMed         Abstract available
    
    

    
    J Hepatol

66. AKCA M, Ketenci YB, Demiroz H, Avcioglu U, et al
    Concerns on Rivaroxaban Use in Cirrhosis: Pharmacokinetic, Safety, and Bleeding Risk Considerations.
    J Hepatol. 2025 Sep 17:S0168-8278(25)02489-4. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
67. LIN YJ, Ou DL, Su YY, Hsu CL, et al
    Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration.
    J Hepatol. 2025 Sep 17:S0168-8278(25)02471-7. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
68. MAURO E, de Castro T, Zeitlhoefler M, Hackshaw A, et al
    Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma.
    J Hepatol. 2025 Sep 22:S0168-8278(25)02492-4. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
69. HSU C
    Engineered T cell therapy for hepatocellular carcinoma: the dawn of precision immunotherapy?
    J Hepatol. 2025 Sep 23:S0168-8278(25)02491-2. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
70. ZHANG T
    RIPK3 in acutely decompensated cirrhosis: prognostic promise and analytic pitfalls.
    J Hepatol. 2025 Sep 24:S0168-8278(25)02499-7. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
71. VERMA N, Kaur P, Garg P, Ranjan V, et al
    Corrigendum to "Clinical and pathophysiological characteristics of non-acute decompensation of cirrhosis" [J Hepatol (2025) https://doi.org/10.1016/j.jhep.2025.02.028].
    J Hepatol. 2025 Sep 25:S0168-8278(25)02475-4. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
72. LISMAN T, Puente A, Garcia-Pagan JC
    Anticoagulant therapy to delay disease progression in patients with cirrhosis - reponse to Acka et al., Bot et al. and Feng et al.
    J Hepatol. 2025 Sep 25:S0168-8278(25)02495-X. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
73. GALANAKIS V, Gribben C, Munteanu A, Cagna M, et al
    Transcriptomic and epigenetic mechanisms controlling cholangiocytes transdifferentiation into hepatocytes.
    J Hepatol. 2025 Sep 29:S0168-8278(25)02516-4. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
74. KIM HD, Sym SJ, Chon HJ, Kim M, et al
    Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.
    J Hepatol. 2025 Sep 4:S0168-8278(25)02457-2. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
75. ZHANG XF, Zuo XY, Zhu Y, Li JX, et al
    Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma.
    J Hepatol. 2025 Oct 1:S0168-8278(25)02517-6. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
76. RUDLER M
    Preemptive TIPS in patients with cirrhosis and acute variceal bleeding related to gastric varices: The GAVAPROSEC trial.
    J Hepatol. 2025 Oct 6:S0168-8278(25)02476-6. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
77. CHEN F, Tchorz JS
    Postnatal hepatocyte proliferation - challenge and opportunity for gene therapy.
    J Hepatol. 2025 Oct 6:S0168-8278(25)02520-6. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    

    
    Oncogene

78. LI J, Mao S, Yang S, Lou Y, et al
    Targeting JMJD6/PPARgamma/GPX4 axis overcomes ferroptosis resistance and enhances therapeutic efficacy in hepatocellular carcinoma.
    Oncogene. 2025 Sep 30. doi: 10.1038/s41388-025-03581.
    PubMed         Abstract available
    
    
79. WU Z, Duan W, Xiong Y, Liu J, et al
    Publisher Correction: NeuroD1 drives a KAT2A-FDFT1 signaling axis to promote cholesterol biosynthesis and hepatocellular carcinoma progression via histone H3K27 acetylation.
    Oncogene. 2025 Sep 22. doi: 10.1038/s41388-025-03574.
    PubMed        
    
    

    
    PLoS One

80. SAN MARTIN VALENZUELA C, Gallego JJ, Urios A, Correa-Ghisays P, et al
    Motor performance as a predictor of blood levels of ammonia and inflammatory biomarkers in patients with liver cirrhosis.
    PLoS One. 2025;20:e0333029.
    PubMed         Abstract available
    
    
81. NAZARI-ROBATI M, Dehesh T, Shahouzehi B, Roshandel G, et al
    Effects of a polypill on circulating levels of resistin and visfatin in men with non-alcoholic fatty liver disease: A five-year clinical trial.
    PLoS One. 2025;20:e0331121.
    PubMed         Abstract available
    
    
82. MIGNOT V, Fabre O, Legrand R, Bailly S, et al
    FIB-4: A screening tool for advanced liver fibrosis in a cohort of subjects participating in a primary care weight-loss program.
    PLoS One. 2025;20:e0333490.
    PubMed         Abstract available
    
    
83. LOPEZ A, Paturel A, Fares N, Pez F, et al
    Frizzled 7 drives amplification of cancer stem-cell subpopulations and the aggressiveness and poor differentiation of human hepatocellular carcinoma.
    PLoS One. 2025;20:e0332768.
    PubMed         Abstract available
    
    

    
    Transplant Proc

84. LU Z, Sun Y, Wang Y, Sun Y, et al
    A Novel Nomogram for Predicting Recurrence of Hepatocellular Carcinoma After Liver Transplantation.
    Transplant Proc. 2025 Sep 22:S0041-1345(25)00430.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.